Hereditary predisposition to cancer associated with BRIP1 is a tumor susceptibility syndrome of moderate penetrance, primarily related to an increased risk of epithelial ovarian, fallopian tube, and peritoneal cancer. It is due to heterozygous pathogenic variants in BRIP1 and follows an autosomal dominant pattern. Loss of function of this helicase alters DNA repair, favoring genomic instability and malignant transformation.
Hereditary cancer (BRIP1 gene)
The BRIP1 gene encodes the FANCJ helicase, an ATP-dependent protein that interacts with BRCA1. It participates in the repair of interstrand crosslinks, double-strand breaks, and replication fork stalling structures, within the Fanconi anemia and homologous recombination pathway.
Pathogenic variants impair the resolution of stalled replication forks and favor chromosomal breaks. The predisposition is autosomal dominant and of incomplete penetrance: each descendant has a 50% probability of inheriting the variant, although not all carriers develop cancer. The average risk of ovarian cancer by age 80 is approximately 5.8%, but it varies by variant and family history, and is primarily concentrated after age 50. Current evidence does not support a clinically relevant increased risk of breast cancer or other tumors. Biallelic variants cause Fanconi anemia group J, a different autosomal recessive disease.
Symptoms
Genetic predisposition does not produce symptoms by itself. If ovarian, fallopian tube, or peritoneal cancer develops, generally in adulthood, persistent abdominal or pelvic distention or pain, early satiety, urinary or bowel changes, weight loss, and fatigue may appear. These are nonspecific symptoms and some tumors are diagnosed in stages. The clinical expression is variable: many carriers never develop cancer and there is no characteristic physical phenotype.
Disease management
The hereditary predisposition cannot be eliminated, but measures can be taken to reduce the risk. Genetic counseling, individualized assessment, and cascade screening of adult relatives are recommended. Transvaginal ultrasound and CA125 do not reliably detect early ovarian cancer or improve survival, so they are not advised as routine screening. It is recommended to consider risk-reducing bilateral salpingo-oophorectomy between 45 and 50 years of age, after reproductive desire has been fulfilled, or earlier in the case of early-onset family history. The consequences of surgical menopause should be explained, and hormonal treatment considered when appropriate. Deferred oophorectomy is still under investigation. Tumors are treated according to their origin, stage, and biomarkers; there is no specific therapy based solely on BRIP1.
Genes analyzed
Bibliography
Cancer Institute NSW. BRIP1 – risk management (female). eviQ. 2026; ID 4118 v.1.
Clinical Genome Resource. BRIP1 – familial ovarian cancer: Gene-Disease Validity. ClinGen. 2023.
Hanson H, Kulkarni A, Loong L, et al. UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2. J Med Genet. 2023;60(5):417-429.
Ramus SJ, Song H, Dicks E, et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst. 2015;107(11):djv214.
